奥克列珠单抗
芬戈莫德
多发性硬化
医学
美罗华
复发-缓解
肿瘤科
内科学
免疫学
淋巴瘤
作者
Lisa Graille-Avy,Clémence Boutière,Camille Rigollet,Marine Perriguey,Audrey Rico,Sarah Demortière,Pierre Durozard,Frédéric Hilezian,Frédéric Vély,P Bertault-Péres,Jean Pelletier,Adil Maarouf,Bertrand Audoin
标识
DOI：10.1212/nxi.0000000000200231
摘要
Real-life studies noted that the risk of disease activity in multiple sclerosis (MS) after switching to rituximab (RTX) or ocrelizumab (OCR) may be unequal depending on prior disease-modifying therapy (DMT), with a higher risk associated with fingolimod (FING).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
学术文献互助
cdercder
Copyright
Nole
大力的冬萱
zzzz
嘻嘻哈哈
OK
liuzhuohao
1111111111
行走的荷尔蒙
Alex_T
lizishu
ale
美满的访旋
超帅的忆曼
sagitar
林夕
Twonej
皖公网安备34019202002308
